Global Pancreatic Cancer Market Size, Forecast, and Trend Highlights Over 2025-2037
Pancreatic Cancer Market size was over USD 2.48 billion in 2024 and is anticipated to reach USD 13.01 billion by the end of 2037, growing at around 13.6% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of pancreatic cancer is estimated at USD 2.72 billion.
The growth in the market is majorly attributed to the rising prevalence of associated malignancies across the world. According to a 2023 NLM article, the worldwide incidence of this carcinoma was 4.9 per 100,000, while having a mortality/incidence ratio of 94.0%. It also mentioned that the maximum annual new onsets were observed among people aged over 70 and between 50 and 69. On the other hand, WHO projected the global population of the age group of 60 and over to surpass 2.1 billion by 2050. Another estimation from the Journal of Gastrointestinal Oncology, released in July 2021, revealed that the number of new incidences of pancreatic cancer (PC) around the globe was 400,000 per year. This demographic represents a growing consumer base in this field.
Several studies have proven the importance of early detection to attain the best outcomes from the use of therapies available in the market. In support of this fact, in June 2021, a cost-effectiveness trial on risk-based PC screening in patients with new-onset diabetes (NOD) was published by the National Comprehensive Cancer Network. It presented a base case cost of USD 63,063.0 per quality-adjusted life years (QALY) gained, establishing this method of screen detection to be a cost-effective option for U.S. residents. Furthermore, dedicated companies are continuously investing in R&D to develop long-acting and safer therapeutics with affordable payers’ pricing to improve public access to advanced treatment.
Pancreatic Cancer Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing R&D activity and investments: The growing frequency and count of financially funded research projects are propelling progress in the pancreatic cancer market. These efforts to identify novel agents and combined therapies to treat both metastatic and locally advanced PCs are expanding the pipeline of this sector. For instance, in September 2024, the City of Hope received a private fund of USD 150.0 million to provide economic support to the leading research cohorts across the U.S. with promising advancements and discoveries. Similarly, in October 2024, the University of Michigan Health earned a grant of USD 50.0 million to construct the Rogel and Blondy Center, revolutionizing the diagnosis and treatment of PC.
- Improvements in therapy kinetics and detection accuracy: Backed by technologically advanced laboratory and clinical tools, the existing portfolio of the market is improving. The introduction of AI and single-cell analysis in anti-cancer drug discovery is enhancing the treatment prognosis and quality of life of patients. Emerging platforms such as mRNA therapeutics and oncolytic viruses are also accelerating the sector’s worldwide penetration. On this note, in October 2024, Oncolytics Biotech shared its plans to explore the potential of pelareorep in pancreatic cancer by conducting a GOBLET study. This trial is funded by The Pancreatic Cancer Action Network (PanCAN).
Challenges
- Growing concerns about adverse reactions and long-term efficacy: The side effects of harsh treatment methods, such as chemotherapy, include pain, dizziness, fever, vomiting, and frequent bowel movements. Additionally, the side effects of radiation therapy cause diarrhea, shortness of breath, change in taste, and urinary & bladder problems. All these factors accumulatively create hesitation among patients about adopting solutions from the market. However, rigorous R&D and large-scale evaluation have the potential to establish a strong safety profile for new therapies, helping companies gain maximum consumer adherence and regulatory compliance.
Pancreatic Cancer Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.6% |
|
Base Year Market Size (2024) |
USD 2.48 billion |
|
Forecast Year Market Size (2037) |
USD 13.01 billion |
|
Regional Scope |
|
Pancreatic Cancer Segmentation
Type (Chemotherapy, Targeted Therapy)
The chemotherapy segment is estimated to account for a 55% share of the global pancreatic cancer market by 2037. Despite the side effects, this method of isolating carcinoma cells in tumor formation is still one of the most prescribed and highly effective curatives. In this regard, a nationwide population-based study, conducted in Korea, was published by ScienceDirect in August 2023, concluding the proportion of PC patients undergoing chemotherapy to be 26.6%. It also mentioned that survival rates were significantly improved by following this approach. Furthermore, the use of this curative in several disciplines, such as adjuvants and combination therapies, is also a reason behind this segment’s proprietorship in revenue generation for this sector.
Affected Area (Exocrine, Endocrine)
The exocrine segment is expected to hold 60% of the revenue share in the pancreatic cancer market over the assessed timeline. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body, which is estimated to position this segment as the leading revenue generator in this field. Testifying this fact, NLM discovered over 90.0% of pancreatic cancers across the world to be pancreatic ductal adenocarcinomas (PDACs), 80.0% among which are diagnosed with advanced-stage disease, published in an article in June 2023. It also mentioned that the 5-year survival rate of PDAC cases is only 11.0%, highlighting the priority of clinical explorations in this segment.
Our in-depth analysis of the global pancreatic cancer market includes the following segments:
|
Type |
|
|
Affected Areas |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPancreatic Cancer Industry - Regional Synopsis
North American Market Forecast
The pancreatic cancer market in North America is projected to be the largest shareholder, accounting for 32% throughout the analyzed timeframe. The region’s leadership is attributed majorly to the increasing adoption of new technologies to deliver better cancer care and outcomes. Ongoing advancements and improved public access to accurate diagnosis and early intervention are creating a progressive atmosphere in this landscape, attracting global leaders to participate. In addition, the enlarging patient pool, where the rate of PC incidence was 8.0 per 100,000 till 2023 (NLM), is also fueling demand in this sector. Furthermore, the region’s dominant captivity in the precision oncology industry, poised to capture 43.0% by 2037, is making North America the hub of innovation for this field.
The U.S. is augmenting the market with several driving factors such as the enlarging patient pool, supportive regulatory framework, and increasing R&D activities. As per a 2023 NLM article, PC is the 3rd leading cause of mortality in this country, accounting for 62,200 and 48,800 new and death cases each year, respectively. Simultaneously, in February 2024, the FDA provided marketing clearance to the combination chemotherapy, NALIRIFOX, for use as a first-line solution for metastatic pancreatic cancer with no previous treatment received. On the other hand, in January 2024, PanCAN collaborated with the Global Coalition for Adaptive Research (GCAR) to leverage the capabilities of its adaptive clinical trial platform, Precision Promise, escalation R&D to create new therapeutics for PC.
APAC Market Statistics
Asia Pacific is predicted to hold a 28% share of the global pancreatic cancer market by the end of 2037. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is propelling its augmentation. Its strong emphasis on pharmaceutical advances and oncological clinical trials to develop new drugs is also estimated to magnify its significance. In this regard, in September 2024, Eisai Co., in collaboration with the National Cancer Center of Japan, announced the commencement of investigator-initiated clinical studies to establish an anti-cancer drug discovery and development system. This initiation was based on the recent findings, demonstrating 38.1% tumor shrinkage in various malignancies, including pancreatic cancer, with the use of a targeted protein degrader, E7820.
India is emerging as a lucrative trading landscape and a leading innovator in the market. The nationwide presence of high-risk patients is enlarging the consumer base in this field, attracting global leaders to invest in this country. Out of all countries, this country marked the 2nd highest rise in incidence, 3.7%, in the world among females in 2022, as per NLM study. Thus, with an intention to expand its portfolio, Servier launched a new treatment option, Onivyde (nanoliposomal irinotecan), for metastatic PC residents in India, in October 2024. Moreover, this scenario indicates a steadily growing demand and a progressive clinical development culture in this field.
Companies Dominating the Pancreatic Cancer Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG Pfizer Inc.
- Aduro Biotech Inc.
- Clovis Oncology Inc.
- NewLink Genetics Corp
- Infinity Pharmaceuticals, Inc.
- Celgene Corporation
- Novocure
- AIM ImmunoTech Inc.
The market is propagating with the continuous R&D activity and cohort, led by key players. They are investing heavily in developing new treatment alternatives with higher response rates and survival possibilities. For instance, in December 2024, NANOBIOTIX shared updates from the phase I trial on radiotherapy-activated NBTXR3 (JNJ-1900), treating patients with locally advanced pancreatic cancer or borderline resectable pancreatic cancer. They revealed the completion of the dose escalation and dose expansion parts of this evaluation process, conducted by The University of Texas MD Anderson Cancer Center. These research initiatives further inspire more companies to participate in this field. Such key players are:
In the News
- In April 2025, Novocure shared its plans to demonstrate positive results from the Phase 3 PANOVA-3 trial at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO). This evaluation showed the effectiveness of its Tumor Treating Fields (TTFields) therapy for treating unresectable, locally advanced pancreatic cancer.
- In January 2025, AIM ImmunoTech outlined its expected upcoming milestones from the Phase 1b/2 trials, funded by the consortium of AstraZeneca and Erasmus Medical Center. It will test the efficacy of the combination therapy of Durvalumab and Ampligen for metastatic pancreatic ductal adenocarcinoma.
Author Credits: Radhika Pawar
- Report ID: 5299
- Published Date: May 06, 2025
- Report Format: PDF, PPT
